↓ Skip to main content

GLP-1/glucagon receptor co-agonism for treatment of obesity

Overview of attention for article published in Diabetologia, July 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
1 news outlet
twitter
119 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
50 Dimensions

Readers on

mendeley
66 Mendeley
Title
GLP-1/glucagon receptor co-agonism for treatment of obesity
Published in
Diabetologia, July 2017
DOI 10.1007/s00125-017-4354-8
Pubmed ID
Authors

Miguel A. Sánchez-Garrido, Sara J. Brandt, Christoffer Clemmensen, Timo D. Müller, Richard D. DiMarchi, Matthias H. Tschöp

Abstract

Over a relatively short period, obesity and type 2 diabetes have come to represent a large medical and economic burden to global societies. The epidemic rise in the prevalence of obesity has metabolic consequences and is paralleled by an increased occurrence of other diseases, such as diabetes, cancer and cardiovascular complications. Together, obesity and type 2 diabetes constitute one of the more preventable causes of premature death and the identification of novel, safe and effective anti-obesity drugs is of utmost importance. Pharmacological attempts to treat obesity have had limited success, with notable adverse effects, rendering bariatric surgery as the only current therapy for substantially improving body weight. Novel unimolecular, multifunctional peptides have emerged as one of the most promising medicinal approaches to enhance metabolic efficacy and restore normal body weight. In this review, we will mainly focus on the discovery and translational relevance of dual agonists that pharmacologically function at the receptors for glucagon and glucagon-like peptide-1. Such peptides have advanced to clinical evaluation and inspired the pursuit of multiple related approaches to achieving polypharmacy within single molecules.

Twitter Demographics

The data shown below were collected from the profiles of 119 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 66 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 24%
Student > Master 11 17%
Student > Ph. D. Student 9 14%
Student > Bachelor 8 12%
Other 6 9%
Other 9 14%
Unknown 7 11%
Readers by discipline Count As %
Medicine and Dentistry 20 30%
Pharmacology, Toxicology and Pharmaceutical Science 7 11%
Agricultural and Biological Sciences 6 9%
Biochemistry, Genetics and Molecular Biology 5 8%
Neuroscience 4 6%
Other 9 14%
Unknown 15 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 77. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 October 2018.
All research outputs
#250,205
of 14,544,639 outputs
Outputs from Diabetologia
#165
of 4,030 outputs
Outputs of similar age
#9,643
of 268,139 outputs
Outputs of similar age from Diabetologia
#7
of 78 outputs
Altmetric has tracked 14,544,639 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,030 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.9. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,139 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 78 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.